**Supplemental Table 2.** DCM/HF risk associated with MoM THA versus CoC THA: sensitivity analyses

|  |  |  |
| --- | --- | --- |
| Sensitivity analyses models | Number of incident DCM/HF | Implantation with MoM THA versus CoC THA(MoM-CoC subcohort) |
|  | MoM | CoC | HR\* (95% CI) | p value |
| Time-dependent covariates: revision with a MoM THA, contralateral MoM THA | 815 | 5379 | 1.10 (1.02-1.19) | 0.013 |
| Age as timescale and stratification by birth cohort | 815 | 5379 | 1.09 (1.01-1.18) | 0.024 |
| Propensity score (IPTW) | 815 | 5379 | 1.08 (1.00-1.17) | 0.037 |
| Fine-Gray model | 815 | 5379 | 1.12 (1.04-1.21) | 0.004 |
| Subgroup of patients without early events: |  |  |  |  |
| During the first month of followup | 803 | 5293 | 1.11 (1.03-1.19) | 0.008 |
| During the first 3 months of followup | 795 | 5232 | 1.11 (1.03-1.20) | 0.007 |
| During the first 6 months of followup | 787 | 5163 | 1.11 (1.03-1.20) | 0.007 |
| DCM/HF coded I42.0 or I50.x | 389 | 2767 | 1.01 (0.93-1.10) | 0.756 |

**\***Hazard ratios adjusted for (complete model): sex and age at baseline, affiliation with the CMUc (free healthcare insurance programs in France), THA fixation with cement, use of a modular neck, history of implantation with TKA, coronary stent, ischemic cardiovascular disease, atrial fibrillation, left ventricular hypertrophy, valvular disease, high blood arterial pressure, depression, sleep disorders, diabetes mellitus, measurable morbid obesity, dyslipidemia, other endocrinal diseases, hemochromatosis, cancer, chronic respiratory disease, sleep apnea, serious infection, chronic kidney disease, chronic inflammatory condition, reimbursement of prescription-only nonsteroidal antiinflammatory drugs, reimbursement of specific psychiatric drugs, measurable history of chronic alcoholism or tobacco smoking; DCM = dilated cardiomyopathy; HF = heart failure; MoM = metal-on-metal; CoC = ceramic-on-ceramic; HR = hazard ratio; CI = confidence interval; IPTW = inverse probability of treatment weighted.